Search
Two projects led by The Kids Research Institute Australia have been awarded more than $2.5 million to fund innovative ideas focused, respectively, on combating persistent ear infections and investigating how dangerous fungi invade the bodies of immunocompromised people.
Researchers from The Kids Research Institute Australia have been awarded a $1.1 million NHMRC ‘Targeted Call for Hearing Health’ grant to conduct the first ever study following Aboriginal babies from birth through to five years to uncover the true prevalence of middle ear infections and hearing loss.
Check out our top tips for travelling with an ear infection so that the kids can fly safely and hit the pool in no time.
Middle ear infections are one of the main reasons that children visit a GP, are prescribed antibiotics and need surgery. Aboriginal children are particularly susceptible and commonly suffer from hearing loss which can affect speech and learning.
Wait times for Aboriginal children suffering ear infections could be reduced to less than four weeks thanks to a new The Kids Research Institute Australia research project
Two The Kids Research Institute Australia research teams have been awarded more than $3.5 million to fund innovative projects.
Researchers from the Wesfarmers Centre of Vaccines and Infectious Diseases at The Kids Research Institute Australia have shared their expertise with the community in Cockburn, covering topics ranging from respiratory disease in babies to recurring ear infections in kids.
Congratulations to four outstanding early-career researchers from The Kids Research Institute Australia, who have been awarded BrightSpark Foundation fellowships and project funding for 2026.
Research projects sharing in a $2.1 million funding boost will seek to translate research findings into changes that benefit patients and help the health system run more efficiently.
Australian First Nations children are at very high risk of early, recurrent, and persistent bacterial otitis media and respiratory tract infection. With the PREVIX randomised controlled trials, we aimed to evaluate the immunogenicity of novel pneumococcal conjugate vaccine (PCV) schedules.